Investor Relations
Positioned for Strategic Expansion
Waypoint Biomedical Holdings, Inc. is a publicly traded Nevada holding company focused on identifying, supporting, and growing early-stage biomedical companies preparing for public markets or strategic investment partnerships.
OTC Ticker
WYPH
Incorporated
Nevada, USA
Founded
2004
Why Invest
Investment Highlights
Early-Stage Opportunity
Access to pre-public biomedical companies at early valuations, before broader market exposure.
Compliance-First Structure
Fully restructured under court supervision with regulatory compliance across all key jurisdictions.
Aligned Leadership
Management team with skin in the game — focused on long-term shareholder value, not short-term gains.
OTC Markets Listed
Publicly traded on OTC Markets under ticker WYPH, providing liquidity and transparency for investors.
Our Approach
Investment Strategy
Our four-pillar strategy is designed to create sustainable value at every stage of the biomedical innovation lifecycle.
Step 01
Identify
Source early-stage and pre-public biomedical companies with differentiated technology and clear market pathways.
Step 02
Support
Provide capital, operational expertise, and strategic guidance to accelerate growth and market readiness.
Step 03
Grow
Position portfolio companies for public market entry, strategic acquisition, or institutional investment.
Market Status
OTC Markets Listing
Company
Waypoint Biomedical Holdings, Inc.
Exchange
OTC Markets
Ticker Symbol
WYPH
Incorporation
Nevada, USA
Transfer Agent
PSTC
Compliance
Regulatory Good Standing
Following a court-supervised restructuring in 2025, Waypoint Biomedical Holdings has achieved full regulatory compliance across all key jurisdictions.
Pacific Stock Transfer Company (PSTC) — Transfer Agent
Nevada Secretary of State — Good Standing
OTC Markets — Expert Market designation removed following 2024 & 2025 financial filings
Clark County, Nevada — Court-supervised restructuring completed
2025 Milestone: Expert Market designation removed from OTC Markets following the successful filing of financial statements for fiscal years 2024 and 2025.
Financials
Financial Reporting
Waypoint Biomedical Holdings has filed financial statements for fiscal years 2024 and 2025 with OTC Markets. The company is committed to ongoing financial transparency and timely disclosure as it enters its growth phase.
Ready to Explore an Investment Partnership?
Whether you're an individual investor, institutional partner, or strategic acquirer — we'd like to hear from you. Reach out directly to our President & CEO.
Disclaimer: This page is for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities. Investing in early-stage and OTC-listed companies involves significant risk, including the possible loss of principal. Past performance is not indicative of future results. Please consult a qualified financial advisor before making any investment decisions.